|Day Low/High||93.97 / 94.77|
|52 Wk Low/High||58.59 / 95.44|
A look at possible second-quarter M&A activity in the biotech sector.
Markets continue to meander between being slightly up or slightly down as equities struggle for a direction after yesterday's big slide. New homes sales for the month of February were above expectations with the average selling price 10% above the s...
Your burning biotech questions answered in our latest mailbag.
We'll answer two of the common questions we have received so far in March.
From ANI Pharmaceuticals to T2 Biosystems, these names look good.
Recently I have noticed some of Wall Street's younger analysts engaging in "multiple creep." They seem to be treating a 12 EBITD (cash flow) multiple like a 12 PE (price to earnings) ratio. Whoops! No problem, for example, paying 25x EPS for ....Unt...
I continue to deploy some of the 'dry powder' into the market after its recent hiccup.
In this tape, weakness may just be a sign of rest and better times to come.
The biotech sector has seen a big rally, but there are still opportunities.
Consumer spending should be more than solid given wage increases.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts to Monday's trending topics.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts to Celgene's plans to acquire Juno Therapeutics for about $9 billion on Monday.
Another New England Patriots win in the Super Bowl could mean bad things for the stock market. What government shutdown?
About a half hour to go before the markets open for the last trading day of the week. Acorda Therapeutics is up more than 10% in pre-market trading on rumors it could be the target of several potential suitors, including Biogen . Juno Therapeutics h...
I've added to my positions in these names on yesterday's intraday silliness.
Bitcoin maintains its decline while U.S. stock futures suggest a rebound from yesterday's small loss. Are you ready for today's trading?
Are you ready to start the week? Here's what needs to be on your radar.
So far: * Retail is quickly reversing yesterdays strength. Dillard's (-$1.70) and Macy's (-$0.70) downside leaders. * Gold quiet, +$1.90. Though optimistic for the full year I would not chase SPDY Gold ETF GLD at these levels. (I am a buyer on weakn...
Stocks put in broad gains supported by tax cuts, bonuses, a weaker dollar and more.
This is the kind of activity you see at a climax low.
Although it appears the low may be in from October, it is hard to trust this stock.
The key feature within the markets is the renewed and continued strength in pharma and biotech which started last week. Allergan , Celgene and Gilead Sciences are upside features. I am not involved and I would not chase big Pharma or biotech.
Some mid afternoon observations: * Small yield flattening in today's session and little change in bond yields. * High yield is slipping a bit. * The U.S. Dollar is strengthening after morning weakness. * Oil down after weeks of strength (-$0.76/ba...
The Nasdaq (QQQs) turn slightly negative as most of the FANGs reverse lower. Retail, generics (Teva and Mylan ), big pharma (Merck and Bristol-Myers Squibb ) and biotech (Allergan , Gilead Sciences , Celgene ) are conspicuous to the downside. Co...